Eletriptan
- Generic Name
- Eletriptan
- Brand Names
- Relpax
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N2O2S
- CAS Number
- 143322-58-1
- Unique Ingredient Identifier
- 22QOO9B8KI
- Background
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
- Indication
For the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
BI 44370 TA in Acute Migraine Attack
Phase 2
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 416
- Registration Number
- NCT00751803
- Locations
- 🇫🇷
1246.4.3301A Boehringer Ingelheim Investigational Site, Nice Cedex 1, France
🇫🇷1246.4.3305B Boehringer Ingelheim Investigational Site, Paris, France
🇧🇪1246.4.32004 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00634985
- Locations
Pfizer Investigational Site
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT00632385
- Locations
- 🇺🇸
Pfizer Investigational Site, Alexandria, Virginia, United States
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Phase 4
Completed
- Conditions
- Migraine
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 71
- Registration Number
- NCT00259649
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
Phase 4
Completed
- Conditions
- Migraine
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00174395
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath